Presentations IADR 2021 Poster Presentation: "Novel lysine-gingipain inhibitor atuzaginstat (COR388) is efficacious in a mouse model of periodontal disease." (July 23, 2021) IADR 2021 Poster Presentation: "Gingipain Inhibitors Penetrate And Inhibit Gingipains In Porphyromonas gingivalis Biofilms" (July 23, 2021) Cortexyme Investor Presentation Jefferies Healthcare Conference Cortexyme Corporate Overview June 2021 ASCP 2021 Oral Presentation: “An Update and Baseline Data from the Phase 2/3 Gain Trial of COR388 (Atuzaginstat) a Novel Bacterial Virulence Factor Inhibitor for the Treatment of Alzheimer’s Disease” (June 1-4, 2021) ASCP 2021 Poster Presentation: “An Update and Baseline Data from the Phase 2/3 Gain Trial of COR388 (Atuzaginstat) a Novel Bacterial Virulence Factor Inhibitor for the Treatment of Alzheimer’s Disease” (June 1-4, 2021) SITC 2020 Poster Presentation #676: "PD-L1 is induced by the periodontal pathogen Porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat" (November 9-14, 2020) CTAD 2020 Oral Presentation #OC19: "Phase 2/3 GAIN trial of COR388 (atuzaginstat), a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s disease: Update and baseline Data" (November 5, 2020) AAIC 2020 Poster #47058: “Targeting Porphyromonas gingivalis to treat Alzheimer’s disease and comorbid cardiovascular disease” (July 2020) AAIC 2020 Poster #40578: “COR388 (atuzaginstat), a novel gingipain inhibitor, decreases fragmentation of ApoE in the central nervous system of Alzheimer's disease patients” (July 2020) AAIC 2020 Poster #44023: “Comprehensive Alzheimer’s pathology is induced by Porphyromonas gingivalis infection: COR388 (atuzaginstat) and other gingipain inhibitors protect against synaptic loss” (July 2020) Poster for AAT-AD/PD 2020 Focus Meeting, April 2-5, 2020
IADR 2021 Poster Presentation: "Novel lysine-gingipain inhibitor atuzaginstat (COR388) is efficacious in a mouse model of periodontal disease." (July 23, 2021)
IADR 2021 Poster Presentation: "Gingipain Inhibitors Penetrate And Inhibit Gingipains In Porphyromonas gingivalis Biofilms" (July 23, 2021)
ASCP 2021 Oral Presentation: “An Update and Baseline Data from the Phase 2/3 Gain Trial of COR388 (Atuzaginstat) a Novel Bacterial Virulence Factor Inhibitor for the Treatment of Alzheimer’s Disease” (June 1-4, 2021)
ASCP 2021 Poster Presentation: “An Update and Baseline Data from the Phase 2/3 Gain Trial of COR388 (Atuzaginstat) a Novel Bacterial Virulence Factor Inhibitor for the Treatment of Alzheimer’s Disease” (June 1-4, 2021)
SITC 2020 Poster Presentation #676: "PD-L1 is induced by the periodontal pathogen Porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat" (November 9-14, 2020)
CTAD 2020 Oral Presentation #OC19: "Phase 2/3 GAIN trial of COR388 (atuzaginstat), a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s disease: Update and baseline Data" (November 5, 2020)
AAIC 2020 Poster #47058: “Targeting Porphyromonas gingivalis to treat Alzheimer’s disease and comorbid cardiovascular disease” (July 2020)
AAIC 2020 Poster #40578: “COR388 (atuzaginstat), a novel gingipain inhibitor, decreases fragmentation of ApoE in the central nervous system of Alzheimer's disease patients” (July 2020)
AAIC 2020 Poster #44023: “Comprehensive Alzheimer’s pathology is induced by Porphyromonas gingivalis infection: COR388 (atuzaginstat) and other gingipain inhibitors protect against synaptic loss” (July 2020)
